The use of human placenta hydrolyzate in the treatment of insufficient endometrial proliferation

Abstract

Endometrium dysfunction on the chronic endometritis background is a major cause of infertility and pregnancy loss. The effectiveness of chronic modern endometritis treatment methods is limited. In its basis, the chronic endometritis therapy is a directed action that can reduce the excessive endometrial inflammatory response while reinforcing its regenerative capabilities. The following paper presents the results of the randomized, open and comparative study of the human placenta hydrolyzate Laennek® when treating patients with chronic endometritis and/or failure of endometrial function. Also, the more effective placenta hydrolyzate use for the restoration of endometrial thickness, ovarian function in women with infertility and recurrent miscarriage compared with therapy hepatoprotectors vnitaminnymi and immunomodulatory drugs is demonstrated. Laennek® ‘s positive impact in pregravidal preparation of patients with chronic endometritis by the modulating effects on the immune and inflammatory processes, growth and function of endometrial ovarian autocrine and paracrine regulation.

Keywords

• chronic endometritis
• infertility
• miscarriage
• endometrial dysfunction
• placenta hydrolyzate
• laennek